ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients
Metadata[+] Show full item record
Avoid prescribing an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB) for patients at high risk of vascular events or renal dysfunction. The combination does not reduce poor outcomes, and leads to more adverse drug-related events than an ACE inhibitor or ARB alone. Stength of recommendation: B: 1 large, high-quality randomized controlled trial (RCT).
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.